Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers.
Animals
Humans
Cell Line, Tumor
High-Throughput Screening Assays
Neoplasms
/ drug therapy
Phosphatidylinositol 3-Kinases
/ drug effects
Protein Kinase Inhibitors
/ pharmacology
Proto-Oncogene Proteins c-akt
/ antagonists & inhibitors
Ribosomal Protein S6 Kinases, 70-kDa
/ antagonists & inhibitors
Signal Transduction
/ drug effects
Stereoisomerism
Structure-Activity Relationship
TOR Serine-Threonine Kinases
/ drug effects
Journal
Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531
Informations de publication
Date de publication:
14 10 2021
14 10 2021
Historique:
pubmed:
2
10
2021
medline:
16
2
2022
entrez:
1
10
2021
Statut:
ppublish
Résumé
Herein, we report the discovery of a novel class of quinazoline carboxamides as dual p70S6k/Akt inhibitors for the treatment of tumors driven by alterations to the PI3K/Akt/mTOR (PAM) pathway. Through the screening of in-house proprietary kinase library, 4-benzylamino-quinazoline-8-carboxylic acid amide
Identifiants
pubmed: 34596404
doi: 10.1021/acs.jmedchem.1c01087
doi:
Substances chimiques
MTOR protein, human
EC 2.7.1.1
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Protein Kinase Inhibitors
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Ribosomal Protein S6 Kinases, 70-kDa
EC 2.7.11.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
M2698
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM